+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Total Artificial Heart (Cardiovascular Devices) - Medical Devices Pipeline Product Landscape, 2021

  • PDF Icon

    Report

  • 49 Pages
  • October 2021
  • Region: Global
  • GlobalData
  • ID: 5460009
Total Artificial Heart (Cardiovascular Devices) - Medical Devices Pipeline Product Landscape, 2021

Summary


This Medical Devices sector report, “Total Artificial Heart (Cardiovascular Devices) - Medical Devices Pipeline Product Landscape, 2021" provides comprehensive information about the Total Artificial Heart pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

A Total Artificial Heart is a prosthetic device that is implanted into the body to replace the biological heart. One unit refers to one total artificial heart.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope


  • Extensive coverage of the Total Artificial Heart under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Total Artificial Heart and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy


The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Total Artificial Heart under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Total Artificial Heart Overview
3 Products under Development
3.1 Total Artificial Heart - Pipeline Products by Stage of Development
3.2 Total Artificial Heart - Pipeline Products by Territory
3.3 Total Artificial Heart - Pipeline Products by Regulatory Path
3.4 Total Artificial Heart - Pipeline Products by Estimated Approval Date
3.5 Total Artificial Heart - Ongoing Clinical Trials
4 Total Artificial Heart - Pipeline Products under Development by Companies
4.1 Total Artificial Heart Companies - Pipeline Products by Stage of Development
4.2 Total Artificial Heart - Pipeline Products by Stage of Development
5 Total Artificial Heart Companies and Product Overview
5.1 Abiomed Inc Company Overview
5.1.1 Abiomed Inc Pipeline Products & Ongoing Clinical Trials Overview
5.2 BioLife4D Corp Company Overview
5.2.1 BioLife4D Corp Pipeline Products & Ongoing Clinical Trials Overview
5.3 BiVacor Pty Ltd Company Overview
5.3.1 BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.4 Carmat SAS Company Overview
5.4.1 Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview
5.5 Cleveland Clinic Lerner College of Medicine Company Overview
5.5.1 Cleveland Clinic Lerner College of Medicine Pipeline Products & Ongoing Clinical Trials Overview
5.6 Cleveland Heart Inc Company Overview
5.6.1 Cleveland Heart Inc Pipeline Products & Ongoing Clinical Trials Overview
5.7 Foster-Miller Inc (Inactive) Company Overview
5.7.1 Foster-Miller Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.8 Griffith University Company Overview
5.8.1 Griffith University Pipeline Products & Ongoing Clinical Trials Overview
5.9 Indian Institute of Technology Kharagpur Company Overview
5.9.1 Indian Institute of Technology Kharagpur Pipeline Products & Ongoing Clinical Trials Overview
5.10 Lausanne University Hospital Company Overview
5.10.1 Lausanne University Hospital Pipeline Products & Ongoing Clinical Trials Overview
5.11 OregonHeart Inc (Inactive) Company Overview
5.11.1 OregonHeart Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.12 ReliantHeart, Inc. Company Overview
5.12.1 ReliantHeart, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.13 Scandinavian Real Heart AB Company Overview
5.13.1 Scandinavian Real Heart AB Pipeline Products & Ongoing Clinical Trials Overview
5.14 Suzhou Tongxin Medical Equipment Co Ltd Company Overview
5.14.1 Suzhou Tongxin Medical Equipment Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.15 Syncardia Systems LLC Company Overview
5.15.1 Syncardia Systems LLC Pipeline Products & Ongoing Clinical Trials Overview
5.16 TEDA International Cardiovascular Hospital Company Overview
5.16.1 TEDA International Cardiovascular Hospital Pipeline Products & Ongoing Clinical Trials Overview
5.17 University of Tokyo Company Overview
5.17.1 University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview
5.18 Yale University Company Overview
5.18.1 Yale University Pipeline Products & Ongoing Clinical Trials Overview
6 Total Artificial Heart- Recent Developments
6.1 Sep 03, 2021: CARMAT Appoints Ivo Simundic as Sales Manager for the DACH Region to Support the Deployment of the Aeson Artificial Heart in Germany, Austria and Switzerland
6.2 Sep 03, 2021: Realheart enters partnership with software experts Codialist
6.3 May 28, 2021: Realheart granted SEK 500,000 for blood research
6.4 May 07, 2021: CARMAT's Board of Directors is reorganising its governance and proposes the appointment of three new directors to support the new strategic phase of industrialization and commercialization
6.5 Apr 06, 2021: Azad Najar a speaker at the ICPM conference April 7-9
6.6 Feb 17, 2021: Abiomed to Present at Upcoming Investor Conferences
6.7 Feb 17, 2021: Abiomed Announces Appointment of Dr. Myron Rolle to Board of Directors
6.8 Jan 28, 2021: Abiomed announces Q3 Earnings Insights
6.9 Dec 01, 2020: CMS updates coverage policies for artificial hearts and ventricular assist devices (VADs)
7 Appendix
7.1 Methodology
7.2 About the Publisher
7.3 Contact the Publisher
7.4 Disclaimer
List of Tables
  • Total Artificial Heart - Pipeline Products by Stage of Development
  • Total Artificial Heart - Pipeline Products by Territory
  • Total Artificial Heart - Pipeline Products by Regulatory Path
  • Total Artificial Heart - Pipeline Products by Estimated Approval Date
  • Total Artificial Heart - Ongoing Clinical Trials
  • Total Artificial Heart Companies - Pipeline Products by Stage of Development
  • Total Artificial Heart - Pipeline Products by Stage of Development
  • Abiomed Inc Pipeline Products & Ongoing Clinical Trials Overview
  • AbioCor II - Product Status
  • AbioCor II - Product Description
  • BioLife4D Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Mini-Heart - Product Status
  • Mini-Heart - Product Description
  • BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • BiVACOR Device - Product Status
  • BiVACOR Device - Product Description
  • Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview
  • Aeson - Product Status
  • Aeson - Product Description
  • Carmat SAS - Ongoing Clinical Trials Overview
  • Aeson - Carmat Total Artificial Heart Early Feasibility Study
  • Aeson - Clinical Evaluation of the Carmat Total Artificial Heart for Patients with Advanced Heart Failure
  • Aeson - Multicentric Prospective Cohort Study in Patients with Irreversible Biventricular Heart Failure to Assess the Efficacy and Safety of Carmat TAH, Its Clinical Utility and Cost, as a Bridge to Transplantation
  • Cleveland Clinic Lerner College of Medicine Pipeline Products & Ongoing Clinical Trials Overview
  • Continuous-Flow Total Artificial Heart - Product Status
  • Continuous-Flow Total Artificial Heart - Product Description
  • Pediatric Continuous-Flow Total Artificial Heart - Product Status
  • Pediatric Continuous-Flow Total Artificial Heart - Product Description
  • Cleveland Heart Inc Pipeline Products & Ongoing Clinical Trials Overview
  • SmartHeart TAH - Product Status
  • SmartHeart TAH - Product Description
  • Foster-Miller Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • MagScrew Total Artificial Heart - Product Status
  • MagScrew Total Artificial Heart - Product Description
  • Griffith University Pipeline Products & Ongoing Clinical Trials Overview
  • Next Generation Artificial Heart - Product Status
  • Next Generation Artificial Heart - Product Description
  • Indian Institute of Technology Kharagpur Pipeline Products & Ongoing Clinical Trials Overview
  • Artificial Heart - Product Status
  • Artificial Heart - Product Description
  • Lausanne University Hospital Pipeline Products & Ongoing Clinical Trials Overview
  • RollingHeart - Product Status
  • RollingHeart - Product Description
  • OregonHeart Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Next Generation Total Artificial Heart - Product Status
  • Next Generation Total Artificial Heart - Product Description
  • ReliantHeart, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Pulse Less Total Artificial Heart - Product Status
  • Pulse Less Total Artificial Heart - Product Description
  • Scandinavian Real Heart AB Pipeline Products & Ongoing Clinical Trials Overview
  • Total Artificial Heart - Product Status
  • Total Artificial Heart - Product Description
  • Suzhou Tongxin Medical Equipment Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • CH-VAD - Product Status
  • CH-VAD - Product Description
  • Syncardia Systems LLC Pipeline Products & Ongoing Clinical Trials Overview
  • SynCardia 50cc Temporary Total Artificial Heart - Destination Therapy - Product Status
  • SynCardia 50cc Temporary Total Artificial Heart - Destination Therapy - Product Description
  • SynCardia 70cc Temporary Total Artificial Heart - Destination Therapy - Product Status
  • SynCardia 70cc Temporary Total Artificial Heart - Destination Therapy - Product Description
  • Syncardia Systems LLC - Ongoing Clinical Trials Overview
  • SynCardia 70cc Temporary Total Artificial Heart - Destination Therapy - SynCardia 70cc Temporary Total Artificial Heart (TAH-t) for Destination Therapy (DT)
  • TEDA International Cardiovascular Hospital Pipeline Products & Ongoing Clinical Trials Overview
  • Artificial Heart - Product Status
  • Artificial Heart - Product Description
  • University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview
  • Helical Flow Total Artificial Heart - Product Status
  • Helical Flow Total Artificial Heart - Product Description
  • Yale University Pipeline Products & Ongoing Clinical Trials Overview
  • Corisma - Product Status
  • Corisma - Product Description
  • Glossary

List of Figures
  • Total Artificial Heart - Pipeline Products by Stage of Development
  • Total Artificial Heart - Pipeline Products by Territory
  • Total Artificial Heart - Pipeline Products by Regulatory Path
  • Total Artificial Heart - Pipeline Products by Estimated Approval Date
  • Total Artificial Heart - Ongoing Clinical Trials

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abiomed Inc
  • BioLife4D Corp
  • BiVacor Pty Ltd
  • Carmat SAS
  • Cleveland Clinic Lerner College of Medicine
  • Cleveland Heart Inc
  • Foster-Miller Inc (Inactive)
  • Griffith University
  • Indian Institute of Technology Kharagpur
  • Lausanne University Hospital
  • OregonHeart Inc (Inactive)
  • ReliantHeart, Inc.
  • Scandinavian Real Heart AB
  • Suzhou Tongxin Medical Equipment Co Ltd
  • Syncardia Systems LLC
  • TEDA International Cardiovascular Hospital
  • University of Tokyo
  • Yale University